155 related articles for article (PubMed ID: 10741729)
21. Overview of phase II trials of MTA in solid tumors.
O'Dwyer PJ; Nelson K; Thornton DE
Semin Oncol; 1999 Apr; 26(2 Suppl 6):99-104. PubMed ID: 10598563
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
23. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
24. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
25. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
26. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
Molina JR; Adjei AA
Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
[TBL] [Abstract][Full Text] [Related]
27. ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer.
Novello S; le Chevalier T
Lung Cancer; 2001 Dec; 34 Suppl 4():S107-9. PubMed ID: 11742713
[TBL] [Abstract][Full Text] [Related]
28. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Misset JL
Semin Oncol; 2002 Feb; 29(1 Suppl 3):36-9. PubMed ID: 11894006
[TBL] [Abstract][Full Text] [Related]
29. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
Adjei AA
Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
32. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Fujimoto S; Chikazawa H
Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
[TBL] [Abstract][Full Text] [Related]
33. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Weitman S; Mangold G; Marty J; Dexter D; Hilsenbeck S; Rake J; Juniewicz P; Von Hoff D
Cancer Chemother Pharmacol; 1999; 43(5):402-8. PubMed ID: 10100596
[TBL] [Abstract][Full Text] [Related]
34. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
35. Phase I trials of pemetrexed.
Fossella FV; Gatzemeier U
Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
[TBL] [Abstract][Full Text] [Related]
36. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
37. Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo.
Nishizaki M; Meyn RE; Levy LB; Atkinson EN; White RA; Roth JA; Ji L
Clin Cancer Res; 2001 Sep; 7(9):2887-97. PubMed ID: 11555607
[TBL] [Abstract][Full Text] [Related]
38. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; De Paola F; Amadori D; Frassineti GL; Zoli W
Clin Cancer Res; 2002 Jan; 8(1):233-9. PubMed ID: 11801564
[TBL] [Abstract][Full Text] [Related]
39. Glutamyl hydrolase and the multitargeted antifolate LY231514.
Rhee MS; Ryan TJ; Galivan J
Cancer Chemother Pharmacol; 1999; 44(5):427-32. PubMed ID: 10501918
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Adjei AA; Erlichman C; Sloan JA; Reid JM; Pitot HC; Goldberg RM; Peethambaram P; Atherton P; Hanson LJ; Alberts SR; Jett J
J Clin Oncol; 2000 Apr; 18(8):1748-57. PubMed ID: 10764436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
